Apellis Pharmaceuticals (APLS) News Today

→ Biden’s $374B Giveaway Into This Sector (From DTI) (Ad)

$47.51

-0.52 (-1.08%)

(As of 04/18/2024 ET)

Source

Source	Headline
	Behind the Scenes of Apellis Pharmaceuticals's Latest Options Trends benzinga.com - April 18 at 2:22 PM
	FY2025 EPS Estimates for Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Reduced by Analyst marketbeat.com - April 18 at 6:48 AM
	Apellis Pharmaceuticals (NASDAQ:APLS) PT Lowered to $57.00 at Wedbush marketbeat.com - April 17 at 3:44 PM
	Apellis Pharmaceuticals (NASDAQ:APLS) Shares Up 2.9% marketbeat.com - April 16 at 1:40 PM
	The 5 Stocks Most Sold By Insiders This Year (APLS) insidertrades.com - April 16 at 10:45 AM
	Apellis Pharmaceuticals' (APLS) "Buy" Rating Reaffirmed at HC Wainwright americanbankingnews.com - April 16 at 3:56 AM
	Apellis Pharmaceuticals (NASDAQ:APLS) Given "Buy" Rating at HC Wainwright marketbeat.com - April 15 at 8:16 AM
	Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Receives Average Rating of "Moderate Buy" from Brokerages americanbankingnews.com - April 15 at 2:48 AM
	Apellis Pharmaceuticals executive sells over $3.7m in stock investing.com - April 11 at 7:42 AM
	Apellis Pharmaceuticals Stock (NASDAQ:APLS), Quotes and News Summary benzinga.com - April 10 at 9:02 PM
	Apellis Pharmaceuticals (NASDAQ:APLS) Stock Price Up 2.3% marketbeat.com - April 10 at 3:24 PM
	Apellis Pharmaceuticals Hold Rating: Navigating Syfovre’s Mixed Reception and Emerging Competition markets.businessinsider.com - April 10 at 10:13 AM
	Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Insider Pascal Deschatelets Sells 69,107 Shares of Stock americanbankingnews.com - April 10 at 5:28 AM
	Insider Selling: Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Insider Sells 69,107 Shares of Stock insidertrades.com - April 10 at 4:53 AM
	Apellis Pharmaceuticals (NASDAQ:APLS) Given "Buy" Rating at Needham & Company LLC americanbankingnews.com - April 10 at 4:24 AM
	Apellis Pharmaceuticals' (APLS) "Buy" Rating Reiterated at Needham & Company LLC marketbeat.com - April 9 at 8:30 AM
	Apellis Pharmaceuticals (NASDAQ:APLS) Shares Down 3.3% marketbeat.com - April 8 at 2:28 PM
	Guru Fundamental Report for APLS nasdaq.com - April 6 at 10:02 AM
	Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Sees Large Growth in Short Interest marketbeat.com - April 5 at 1:58 AM
	Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) globenewswire.com - April 4 at 4:05 PM
	Insider Selling: Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) CFO Sells 4,000 Shares of Stock insidertrades.com - April 3 at 4:58 AM
	Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Sees Significant Increase in Short Interest marketbeat.com - April 3 at 2:14 AM
	Apellis Pharmaceuticals (NASDAQ:APLS) Trading Down 8.6% marketbeat.com - April 2 at 5:46 PM
	Apellis Pharmaceuticals to Host a Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference globenewswire.com - April 1 at 7:00 AM
	Apellis Pharmaceuticals (APLS) Down 8.7% Since Last Earnings Report: Can It Rebound? finance.yahoo.com - March 28 at 2:15 PM
	Decoding 15 Analyst Evaluations For Apellis Pharmaceuticals markets.businessinsider.com - March 27 at 3:34 PM
	Apellis Pharmaceuticals' (APLS) "Neutral" Rating Reaffirmed at Mizuho marketbeat.com - March 27 at 2:14 PM
	Insider Sell: Chief Business & Strategy Officer Mark Delong Sells 9,913 Shares of Apellis ... finance.yahoo.com - March 27 at 8:25 AM
	Vanguard Group Inc. Increases Position in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) marketbeat.com - March 27 at 4:26 AM
	Apellis Pharmaceuticals (NASDAQ:APLS) Trading Up 4.9% marketbeat.com - March 26 at 4:21 PM
	Assenagon Asset Management S.A. Has $128.40 Million Holdings in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) marketbeat.com - March 25 at 5:59 PM
	A. Sinclair Dunlop Sells 18,681 Shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Stock insidertrades.com - March 22 at 5:00 AM
	Apellis Pharmaceuticals officer sells $564k in company stock investing.com - March 21 at 6:49 PM
	Deutsche Bank AG Sells 154,072 Shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) marketbeat.com - March 21 at 4:09 AM
	Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Director A. Sinclair Dunlop Sells 18,681 Shares marketbeat.com - March 20 at 7:35 PM
	Apellis Pharmaceuticals (NASDAQ:APLS) Trading Down 3.9% on Insider Selling marketbeat.com - March 20 at 10:35 AM
	Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Insider Mark Jeffrey Delong Sells 9,913 Shares insidertrades.com - March 20 at 7:08 AM
	Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) CAO James George Chopas Sells 184 Shares insidertrades.com - March 19 at 5:58 AM
	Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) CAO Sells $10,388.64 in Stock marketbeat.com - March 18 at 5:33 PM
	APLS Mar 2024 56.000 put finance.yahoo.com - March 16 at 6:29 PM
	APLS Mar 2024 59.000 call finance.yahoo.com - March 16 at 8:29 AM
	APLS Mar 2024 50.000 put finance.yahoo.com - March 16 at 8:29 AM
	Nur Nicholson Sells 11,220 Shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Stock insidertrades.com - March 16 at 5:58 AM
	Peering Into Apellis Pharmaceuticals's Recent Short Interest benzinga.com - March 15 at 1:20 PM
	Jacobs Levy Equity Management Inc. Makes New $4.17 Million Investment in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) marketbeat.com - March 15 at 4:14 AM
	Apellis Pharmaceuticals Inc (APLS) CTO Nur Nicholson Sells 11,220 Shares finance.yahoo.com - March 14 at 7:14 PM
	Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Insider Sells $645,823.20 in Stock marketbeat.com - March 14 at 4:39 PM
	Apellis Pharmaceuticals (NASDAQ:APLS) Trading Down 4.3% marketbeat.com - March 12 at 1:24 PM
	Polar Capital Holdings Plc Grows Stock Holdings in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) marketbeat.com - March 11 at 1:56 PM
	Apellis Appoints Leading Expert Dr. Philip Ferrone as Chief Medical Retina Advisor globenewswire.com - March 11 at 7:00 AM

Get Apellis Pharmaceuticals News Delivered to You Automatically

Biden’s $374B Giveaway Into This Sector (Ad)

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

Click here for the full story

APLS Media Mentions By Week

APLS Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

APLS
News Sentiment
▼
0.38

0.49
▲
Average
Medical
News Sentiment

APLS News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

APLS Articles
This Week
▼
11

8
▲
APLS Articles
Average Week

Get Apellis Pharmaceuticals News Delivered to You Automatically

Related Companies and Tools

Related Companies:

Headlines Tools:

This page (NASDAQ:APLS) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Apellis Pharmaceuticals (APLS) News Today

APLS Media Mentions By Week

APLS Media Sentiment

APLS News Coverage

Related Companies and Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info